MIM
CRNX

MetLife Investment Management’s Crinetics Pharmaceuticals CRNX Stock Holding History

MetLife Investment Management’s Portfolio CRNX Stock Details CRNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.26M Buy
60,361
+6,035
+11% +$224K 0.01% 1080
2026
Q1 		$1.97M Buy
54,326
+4,508
+9% +$201K 0.01% 1070
2025
Q4 		$2.32M Sell
49,818
-3,596
-7% -$160K 0.01% 1008
2025
Q3 		$2.22M Hold
53,414
– – 0.01% 1034
2025
Q2 		$1.54M Hold
53,414
– – 0.01% 1122
2025
Q1 		$1.79M Buy
53,414
+394
+0.7% +$14.7K 0.01% 1092
2024
Q4 		$2.71M Buy
53,020
+8,085
+18% +$452K 0.01% 888
2024
Q3 		$2.3M Hold
44,935
– – 0.01% 946
2024
Q2 		$2.01M Buy
44,935
+10,916
+32% +$504K 0.01% 968
2024
Q1 		$1.59M Hold
34,019
– – 0.01% 1058
2023
Q4 		$1.21M Hold
34,019
– – 0.01% 1200
2023
Q3 		$1.01M Buy
34,019
+5,972
+21% +$123K 0.01% 1222
2023
Q2 		$505K Hold
28,047
– – ﹤0.01% 1685
2023
Q1 		$450K Hold
28,047
– – ﹤0.01% 1703
2022
Q4 		$513K Buy
28,047
+792
+3% +$14K ﹤0.01% 1628
2022
Q3 		$535K Buy
27,255
+1,838
+7% +$37.5K ﹤0.01% 1591
2022
Q2 		$474K Hold
25,417
– – ﹤0.01% 1703
2022
Q1 		$558K Buy
25,417
+9,063
+55% +$183K ﹤0.01% 1705
2021
Q4 		$465K Buy
16,354
+4,706
+40% +$116K ﹤0.01% 1547
2021
Q3 		$245K Hold
11,648
– – ﹤0.01% 1961
2021
Q2 		$220K Hold
11,648
– – ﹤0.01% 2105
2021
Q1 		$178K Sell
11,648
-1,084
-9% -$16.8K ﹤0.01% 2117
2020
Q4 		$180K Hold
12,732
– – ﹤0.01% 2035
2020
Q3 		$200K Hold
12,732
– – ﹤0.01% 1866
2020
Q2 		$223K Buy
12,732
+6,897
+118% +$118K ﹤0.01% 1845
2020
Q1 		$85.8K Hold
5,835
– – ﹤0.01% 2160
2019
Q4 		$146K Buy
+5,835
New +$111K ﹤0.01% 2146
2019
Q3 		– Sell
-5,862
Closed -$147K – 2340
2019
Q2 		$147K Buy
+5,862
New +$145K ﹤0.01% 2203

Other funds holding CRNX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
JT
Jupiter Topco New York $245B AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

MetLife Investment Management's CRNX Position: Q2 2026 in Review

MetLife Investment Management increased its Crinetics Pharmaceuticals (CRNX) stake by 11% in Q2 2026, buying an estimated $224K and bringing the position to 60,361 shares worth $2.26M. The position accounts for 0.01% of the portfolio, ranked #1080.

MetLife Investment Management first reported a position in CRNX in Q2 2019 and has held it in 28 quarters since. The position peaked at $2.71M in Q4 2024. 267 funds tracked by Wall St. Rank hold CRNX as of Q2 2026.

  • MetLife Investment Management held 60,361 shares of Crinetics Pharmaceuticals worth $2.26M as of Q2 2026.
  • MetLife Investment Management bought 6,035 Crinetics Pharmaceuticals shares in Q2 2026, an estimated $224K.
  • Crinetics Pharmaceuticals made up 0.01% of MetLife Investment Management's portfolio in Q2 2026, its #1080 holding.
  • MetLife Investment Management first reported a position in Crinetics Pharmaceuticals in Q2 2019 and has held it in 28 quarters since.
  • MetLife Investment Management's Crinetics Pharmaceuticals position peaked at $2.71M in Q4 2024.
  • 267 funds tracked by Wall St. Rank held Crinetics Pharmaceuticals as of Q2 2026.

Based on MetLife Investment Management's 13F filing for Q2 2026, filed 14 Aug 2026.